Mar 28, 2022 / 12:00PM GMT
Operator
Good morning, everyone, and welcome to the Krystal Biotech call and webcast to review Phase III data from the GEM-3 trial. (Operator Instructions) As a reminder, this conference is being recorded. At this time, I'll turn the call over to Krish Krishnan, Chairman and CEO. Sir, please go ahead.
Krish S. Krishnan - Krystal Biotech, Inc. - Founder, Chairman, President & CEO
Good morning, everyone. Thanks for joining us today. to review the more detailed results from the Phase III trial of B-VEC. As you may be aware, these data were presented over the weekend at AAD and concurrently announced via a press release.
Next slide, please. As a reminder, this presentation will contain forward-looking statements based on our current expectations and beliefs. We refer you to the SEC filings for further information.
Next slide. So the goal of the call today is to discuss these more detailed Phase III results, Hubert Chen, our Senior Vice President of Clinical Development will walk you through the AAD presentation, following which Andy Orth, our Chief
Krystal Biotech Inc AAD GEM-3 Phase 3 Data Corporate Call Transcript
Mar 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers